Takeda Feels Confident Of No Entyvio Biosimilars Until Early 2030s
Japanese Firm Notes Challenges In Developing IBD Biologics
Executive Summary
Biosimilar vedolizumab rivals to Takeda’s Entyvio blockbuster will not materialize in the current decade, the Japanese originator has forecasted as part of a significantly extended IP landscape.
You may also be interested in...
EU Approves Takeda’s Injectable Entyvio for IBD
Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.
Takeda's Entyvio approved in Europe for UC and Crohn's
One week after receiving a double win with US regulators, Takeda has secured approval in Europe for Entyvio (vedolizumab) in both its ulcerative colitis and Crohn's disease indications.
Five Big Legal Stories From 2022
Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.